Published in Infect Immun on June 01, 1994
Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun (1995) 6.43
Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1995) 4.76
Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun (1996) 4.68
Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev (2003) 4.14
Mycobacterium avium subsp. paratuberculosis in Veterinary Medicine. Clin Microbiol Rev (2001) 3.58
Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun (1998) 3.14
ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun (2000) 2.87
Negligible genetic diversity of mycobacterium tuberculosis host immune system protein targets: evidence of limited selective pressure. Genetics (2000) 2.63
Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun (2001) 2.62
Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun (1999) 2.57
Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun (1995) 2.39
Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry. Infect Immun (1997) 2.37
Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology (1995) 2.19
Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun (1997) 2.05
Predominant recognition of the ESAT-6 protein in the first phase of interferon with Mycobacterium bovis in cattle. Infect Immun (1997) 2.05
Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun (1999) 1.95
Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun (2003) 1.91
Bacterial glycoproteins: a link between glycosylation and proteolytic cleavage of a 19 kDa antigen from Mycobacterium tuberculosis. EMBO J (1996) 1.74
Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun (2004) 1.65
Cloning, sequencing, and expression of the apa gene coding for the Mycobacterium tuberculosis 45/47-kilodalton secreted antigen complex. Infect Immun (1995) 1.60
Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun (2001) 1.60
Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun (1999) 1.55
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun (1998) 1.53
Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun (2001) 1.50
Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis. Infect Immun (2002) 1.48
Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun (1997) 1.41
A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis (2008) 1.39
Two-dimensional electrophoresis for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins. Infect Immun (1998) 1.38
T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts. Infect Immun (1999) 1.38
Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis. Infect Immun (1998) 1.28
Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun (2004) 1.28
Identification of genes encoding exported Mycobacterium tuberculosis proteins using a Tn552'phoA in vitro transposition system. J Bacteriol (2000) 1.26
Analysis of T cells recruited during delayed-type hypersensitivity to purified protein derivative (PPD) versus challenge with tuberculosis infection. Immunology (1998) 1.24
The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. Infect Immun (2006) 1.24
Identification and characterization of a 29-kilodalton protein from Mycobacterium tuberculosis culture filtrate recognized by mouse memory effector cells. Infect Immun (1998) 1.24
Identification of mycobacterium tuberculosis DNA sequences encoding exported proteins by using phoA gene fusions. J Bacteriol (1995) 1.22
The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology (2007) 1.18
An ex vivo study of T lymphocytes recovered from the lungs of I/St mice infected with and susceptible to Mycobacterium tuberculosis. Infect Immun (1998) 1.17
Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. Infect Immun (1999) 1.15
The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One (2012) 1.14
Induction of cytotoxic T-cell responses against culture filtrate antigens in Mycobacterium bovis bacillus Calmette-Guérin-infected mice. Infect Immun (1997) 1.11
Analysis of culture filtrate and cell wall-associated antigens of Mycobacterium paratuberculosis with monoclonal antibodies. Infect Immun (1997) 1.11
Influence of mouse strain and vaccine viability on T-cell responses induced by Mycobacterium bovis bacillus Calmette-Guérin. Infect Immun (1995) 1.10
Virulence plasmid of Rhodococcus equi contains inducible gene family encoding secreted proteins. Infect Immun (2001) 1.10
Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice. Proc Natl Acad Sci U S A (1998) 1.10
Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. Infect Immun (2000) 1.08
Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol (2008) 1.08
T-cell epitope mapping of the three most abundant extracellular proteins of Mycobacterium tuberculosis in outbred guinea pigs. Infect Immun (1999) 1.08
Enhanced production of recombinant Mycobacterium tuberculosis antigens in Escherichia coli by replacement of low-usage codons. Infect Immun (2000) 1.08
Identification and characterization of a novel extracellular ferric reductase from Mycobacterium paratuberculosis. Infect Immun (1998) 1.05
Proteomic profiling of Mycobacterium tuberculosis identifies nutrient-starvation-responsive toxin-antitoxin systems. Mol Cell Proteomics (2013) 1.05
Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun (2005) 1.03
Epitope focus, clonal composition and Th1 phenotype of the human CD4 response to the secretory mycobacterial antigen Ag85. Clin Exp Immunol (2001) 1.01
Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis. Infect Immun (2002) 1.01
Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes. Infect Immun (2000) 1.00
Th1 adjuvant N-acetyl-D-glucosamine polymer up-regulates Th1 immunity but down-regulates Th2 immunity against a mycobacterial protein (MPB-59) in interleukin-10-knockout and wild-type mice. Infect Immun (2001) 0.99
Designing a vaccine for tuberculosis. BMJ (1996) 0.98
Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and interleukin-2 for protection against bovine tuberculosis. Infect Immun (2000) 0.97
Effective, nonsensitizing vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice. Infect Immun (1998) 0.97
Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect Immun (2002) 0.96
Characterization of a novel Mycobacterium bovis secreted antigen containing PGLTS repeats. Infect Immun (1995) 0.96
Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone. Clin Vaccine Immunol (2008) 0.96
Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J Immunol (2014) 0.95
Proteins of the Rpf family: immune cell reactivity and vaccination efficacy against tuberculosis in mice. Infect Immun (2003) 0.94
Protective effect of DNA immunization against mycobacterial infection is associated with the early emergence of interferon-gamma (IFN-gamma)-secreting lymphocytes. Clin Exp Immunol (2000) 0.94
Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine. Immunology (2001) 0.92
Heterologous expression of the Mycobacterium tuberculosis gene encoding antigen 85A in Corynebacterium glutamicum. Appl Environ Microbiol (1997) 0.91
Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology (2006) 0.91
Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect Immun (2005) 0.90
Antigen specificity of T-cell response to Mycobacterium avium infection in mice. Infect Immun (2000) 0.89
Unique model of dormant infection for tuberculosis vaccine development. Clin Vaccine Immunol (2006) 0.89
Human Mycobacterium tuberculosis CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library. PLoS One (2013) 0.89
Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur. BMC Microbiol (2011) 0.88
A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire. Clin Vaccine Immunol (2009) 0.87
Analysis of immune responses against a wide range of Mycobacterium tuberculosis antigens in patients with active pulmonary tuberculosis. Clin Vaccine Immunol (2012) 0.87
Cloning of the gene encoding a 22-kilodalton cell surface antigen of Mycobacterium bovis BCG and analysis of its potential for DNA vaccination against tuberculosis. Infect Immun (2000) 0.85
Distinct differences in repertoires of low-molecular-mass secreted antigens of Mycobacterium avium complex and Mycobacterium tuberculosis. J Clin Microbiol (2000) 0.85
Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology (2007) 0.84
Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning. Vaccine (2008) 0.84
Vaccination of guinea pigs with nutritionally impaired avirulent mutants of Mycobacterium bovis protects against tuberculosis. Infect Immun (1999) 0.84
CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection. Eur J Immunol (2012) 0.83
Immunogenicity and safety of Mycobacterium tuberculosis culture filtrate proteins in non-human primates. Clin Exp Immunol (2000) 0.83
Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J (2010) 0.82
Live attenuated Salmonella vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection against Mycobacterium tuberculosis. Infect Immun (2011) 0.82
The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection. Immunology (2003) 0.82
Identification of murine H2-Dd- and H2-Ab-restricted T-cell epitopes on a novel protective antigen, MPT51, of Mycobacterium tuberculosis. Infect Immun (2004) 0.82
Evaluation of humoral and cell-mediated inducible immunity to Haemophilus ducreyi in an animal model of chancroid. Infect Immun (1996) 0.80
Identification of an HLA-A*0201-restricted T-cell epitope on the MPT51 protein, a major secreted protein derived from Mycobacterium tuberculosis, by MPT51 overlapping peptide screening. Infect Immun (2008) 0.79
Comparative evaluation of MPT83 (Rv2873) for T helper-1 cell reactivity and identification of HLA-promiscuous peptides in Mycobacterium bovis BCG-vaccinated healthy subjects. Clin Vaccine Immunol (2011) 0.79
T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections. Clin Dev Immunol (2010) 0.79
Processing and presentation of an antigen of Mycobacterium avium require access to an acidified compartment with active proteases. Infect Immun (1996) 0.78
Mycobacterium tuberculosis-secreted protein antigens: immunogenicity in baboons. J Clin Immunol (2000) 0.78
Protective effects of membrane-anchored and secreted DNA vaccines encoding fatty acid-binding protein and glutathione S-transferase against Schistosoma japonicum. PLoS One (2014) 0.78
Mycobacterium tuberculosis Des protein: an immunodominant target for the humoral response of tuberculous patients. Infect Immun (1997) 0.78
Cell-mediated immune responses of healthy laboratory volunteers to sonicate antigens prepared from the most prevalent strains of Mycobacterium tuberculosis from South India harboring a single copy of IS6110. Clin Diagn Lab Immunol (2003) 0.78
Expression and immunogenicity of hemagglutinin A from Porphyromonas gingivalis in an avirulent Salmonella enterica serovar typhimurium vaccine strain. Infect Immun (2000) 0.78
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
Cellular resistance to infection. J Exp Med (1962) 30.96
Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem (1981) 29.21
Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med (1988) 7.02
Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol (1989) 5.92
T cell response to Mycobacterium tuberculosis. J Infect Dis (1993) 5.53
Lysogeny and transformation in mycobacteria: stable expression of foreign genes. Proc Natl Acad Sci U S A (1988) 4.90
Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun (1992) 3.85
Introduction of foreign DNA into mycobacteria using a shuttle phasmid. Nature (1987) 3.83
Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J Exp Med (1983) 3.79
Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect Immun (1988) 3.79
Proteins released from Mycobacterium tuberculosis during growth. Infect Immun (1991) 3.69
Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science (1992) 3.59
Mycobacterial protein antigens: a compilation. Mol Microbiol (1992) 3.35
Intracellular growth of Listeria monocytogenes as a prerequisite for in vivo induction of T cell-mediated immunity. J Immunol (1987) 2.90
Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs. Am Rev Respir Dis (1970) 2.65
Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-kDa protein. Eur J Immunol (1987) 2.45
T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun (1991) 2.43
Human immune response to Mycobacterium tuberculosis antigens. Infect Immun (1991) 2.39
The secreted antigens of Mycobacterium tuberculosis and their relationship to those recognized by the available antibodies. J Gen Microbiol (1988) 2.38
Failure of killed Listeria monocytogenes vaccine to produce protective immunity. Nature (1982) 2.38
Specificity of a protective memory immune response against Mycobacterium tuberculosis. Infect Immun (1993) 2.27
Differences in response among inbred mouse strains to infection with small doses of Mycobacterium bovis BCG. Infect Immun (1981) 2.16
Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ (1990) 2.08
Identification of immunodominant antigens during infection with Mycobacterium tuberculosis. Scand J Immunol (1992) 2.05
T-cell memory: the connection between function, phenotype and migration pathways. Immunol Today (1991) 1.95
Effective nonliving vaccine against experimental tuberculosis in mice. J Bacteriol (1966) 1.83
Duration of immunity to tuberculosis in mice vaccinated intravenously with oil-treated cell walls of Mycobacterium bovis strain BCG. J Immunol (1967) 1.75
Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol (1992) 1.73
Single-dose antenatal tetanus immunisation. Lancet (1973) 1.68
Genetic control of natural resistance to nontuberculous mycobacterial infections in mice. Infect Immun (1986) 1.68
Immunological adjuvants: a role for liposomes. Immunol Today (1990) 1.52
Dimethyl diotadecyl ammonium bromide as adjuvant for delayed hypersensitivity in mice. Immunology (1977) 1.51
A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Immunol Today (1992) 1.36
Simultaneous electroelution of whole SDS-polyacrylamide gels for the direct cellular analysis of complex protein mixtures. J Immunol Methods (1993) 1.32
Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J Immunol (1989) 1.05
Antituberculous vaccination in the guinea pig with non-living vaccines. Am Rev Tuberc (1958) 1.04
Studies on the effect of isoniazid upon the antituberculous immunity induced by BCG vaccination. Tubercle (1959) 1.03
Stimulation of chemiluminescence and resistance against aerogenic influenza virus infection by synthetic muramyl dipeptide combined with trehalose dimycolate. Infect Immun (1984) 1.02
The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res Hum Retroviruses (1992) 0.94
Murine IgG isotype responses to the Plasmodium cynomolgi circumsporozoite peptide (NAGG)5. I. Effects of carrier, copolymer adjuvants, and lipopolysaccharide on isotype selection. J Immunol (1991) 0.91
Comparison of muramyl dipeptide, trehalose dimycolate, and dimethyl dioctadecyl ammonium bromide as adjuvants in Brucella abortus 45/20 vaccines. Infect Immun (1980) 0.91
Protection by BCG vaccination--a review of Australian epidemiology. Dev Biol Stand (1986) 0.82